AJCC Staging 8th Edition Highlights
By Jennifer Rohleder BS CTR
SME for Oncology Data Management and Education
Several primary sites that have under gone significant changes with the implementation of the 8th Edition of AJCC Staging manual. I have included only a few key changes to remind you that it is very important to use the AJCC manual (rather than software pull-down menus, slides from presentations, or other short cuts) to identify and record any elements required for staging. The best way to learn is directly from the source!
- Prognostic staging will require T,N,M; grade, HER2; and estrogen and progesterone status.
- Genomic profiles will also factor into the stage.
- Pathologic disease is now considered T2 and is no longer sub classified by extent of disease or laterality.
- Tumor Grade includes both the Gleason Score and the grade group
- The prognostic stage group III includes organ-confined disease based on PSA and Gleason/grade group
- Head and Neck:
- New staging model for Human Papilloma Virus (HPV) associated oropharynx cancer
- Tumor staging for oral cavity, nasopharynx and cutaneous Squamous and basal cell carcinoma
- Change in classification of unknown primary for head and neck cancer
- Expanded staging for nodal disease
- Restaging for nasopharynx will include (+/-) Epstein-barr virus (EBV)
- Restaging for orpharynx will include (+) HPV
- Restaging for oropharynx and hypopharynx (-) HPV
Reference: AJCC Stage Manual Eighth Edition